Mylan had challenged Biogen’s ‘514 patent, which covers the treatment of multiple sclerosis with 480mg dose of dimethyl fumarate (DMF), the active ingredient of Tecfidera.However, although the company plans to appeal the West Virginia court’s decision on the patent, it brings its opponent Mylan a step closer to launch its dimethyl fumarate generic product upon the receipt of the FDA approval.